CMS advises IBL International on its disposal to Tecan Group

Hamburg - Tecan Group AG, a leading global provider of laboratory instruments and solutions, based in Männedorf, Switzerland, acquires the IBL International-Group, whose main activities are carried out in their headquarter in Hamburg. IBL International GmbH is specialised in the area of immunoassays.

A team of CMS Hasche Sigle and CMS Derks Star Busman advised IBL extensively on the transaction. Lead Partners were Hilke Herchen and Reinout Slot, which advised IBL International B.V., the group's Dutch Holding company on behalf of the sellers. Before the transaction the Dutch private equity and venture capital investors Wadinko and Middenduin Life Sciences were majority shareholders of IBL International B.V.

IBL International has been developing and producing immunoassays for three decades. Its broad product portfolio, including enzyme-, radio-, and luminescence immunoassays is distributed worldwide.

Tecan is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. With its staff of about 1,200 the company generated sales of CHF 388 million in 2013.

CMS Germany

Dr. Hilke Herchen, Lead Partner
Dr. Nils Maack
Dr. Ronald Brettner, all Corporate/M&A
Dr. Jörn Witt
Dr. Roland Wiring, both Lifesciences
Dr. Hermann Müller
Dr. Oliver Freitag, both Regulatory

CMS Netherlands

Reinout Slot, Lead Partner
Christian Delgado, both Corporate/M&A
Marlene Veenman, Corporate Finance

Press Contact
[email protected]